Meeting
2016 ASCO Annual Meeting
Rising financial burden of targeted oral anticancer medications on the Medicare Part D program and its beneficiaries.
Authors
Ya-Chen T. Shih
The University of Texas MD Anderson Cancer Center, Houston, TX
Ya-Chen T. Shih , Ying Xu , Fabrice Smieliauskas , Lei Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6625)
DOI
10.1200/JCO.2016.34.15_suppl.6625
Abstract #
6625
Poster Bd #
107
Abstract Disclosures
Similar Posters
First Author: Nivedita Arora
Poster
2021 ASCO Quality Care Symposium
Medicare Part D spending for the 10 costliest oral anticancer drugs.
First Author: Kaitlyn McBride
Poster
2023 ASCO Quality Care Symposium
The high cost of supplements, complementary therapy, and alternative medicine in patients with breast cancer.
First Author: Kaitlyn Lapen
Poster
2021 Gastrointestinal Cancers Symposium
Projected 30-day out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
First Author: Arjun Gupta